Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group
AssigneeConjuChem Biotechnologies Inc.
InventorsDominique P. Bridon, Robert S. Dufresne, Nisssab Boudjellab, Martin Robitaille, Peter G. Milner
Life of this patent
Estimating the term…
Abstract
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
Claims10
A modified anti-fusogenic peptide comprising a peptide that has been modified to have a maleimide containing group coupled thereto which is reactive with a thiol group at cysteine 34 of albumin, said peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1. SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 117, SEQ ID NO:
- 118, SEQ ID NO:
- 119, SEQ ID NO:
- 534, SEQ ID NO:
- 535, SEQ ID NO:
- 536, SEQ ID NO:
- 537, SEQ ID NO:
- 538, SEQ ID NO:
- 539, SEQ ID NO:
- 540, and SEQ ID NO:
- 541, wherein said maleimide containing group is attached to said peptide without a linker or via a (2-amino)ethoxy acetic acid (AEA) or a [2-(2-amino) ethoxy] acetic acid (AEEA) linker and said modified anti-fusogenic peptide exhibits an anti-viral and anti-fusogenic activity against human immunodeficiency virus (HIV).
Dependencies are inferred from the claim text.